Medpace Holdings Inc (MEDP) - Net Assets
Based on the latest financial reports, Medpace Holdings Inc (MEDP) has net assets worth $459.07 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.98 Billion) and total liabilities ($1.52 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Medpace Holdings Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $459.07 Million |
| % of Total Assets | 23.24% |
| Annual Growth Rate | 1.21% |
| 5-Year Change | -51.83% |
| 10-Year Change | -24.83% |
| Growth Volatility | 34.24 |
Medpace Holdings Inc - Net Assets Trend (2014–2025)
This chart illustrates how Medpace Holdings Inc's net assets have evolved over time, based on quarterly financial data. Also explore Medpace Holdings Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Medpace Holdings Inc (2014–2025)
The table below shows the annual net assets of Medpace Holdings Inc from 2014 to 2025. For live valuation and market cap data, see how much is Medpace Holdings Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $459.07 Million | -44.39% |
| 2024-12-31 | $825.54 Million | +47.70% |
| 2023-12-31 | $558.95 Million | +44.66% |
| 2022-12-31 | $386.39 Million | -59.45% |
| 2021-12-31 | $952.93 Million | +18.26% |
| 2020-12-31 | $805.78 Million | +10.95% |
| 2019-12-31 | $726.28 Million | +23.16% |
| 2018-12-31 | $589.70 Million | +17.11% |
| 2017-12-31 | $503.53 Million | -17.55% |
| 2016-12-31 | $610.71 Million | +47.70% |
| 2015-12-31 | $413.47 Million | +2.86% |
| 2014-12-31 | $401.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medpace Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44564500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $284.00K | 0.06% |
| Other Comprehensive Income | $-4.91 Million | -1.07% |
| Other Components | $923.67 Million | 201.21% |
| Total Equity | $459.07 Million | 100.00% |
Medpace Holdings Inc Competitors by Market Cap
The table below lists competitors of Medpace Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JCET Group Co Ltd
SHG:600584
|
$11.93 Billion |
|
National Bank of Greece S.A
AT:ETE
|
$11.93 Billion |
|
James Hardie Industries PLC ADR
NYSE:JHX
|
$11.95 Billion |
|
KERRY GRP PLC ADR/1EO-12
F:KRZA
|
$11.95 Billion |
|
Mazagon Dock Shipbuilders Limited
NSE:MAZDOCK
|
$11.92 Billion |
|
Yunnan Chuangxin New Material Co Ltd
SHE:002812
|
$11.92 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
$11.90 Billion |
|
Petronas Chemicals Group Bhd
KLSE:5183
|
$11.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medpace Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 825,545,000 to 459,071,000, a change of -366,474,000 (-44.4%).
- Net income of 451,123,000 contributed positively to equity growth.
- Share repurchases of 917,389,000 reduced equity.
- Other comprehensive income increased equity by 9,837,000.
- Other factors increased equity by 89,955,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $451.12 Million | +98.27% |
| Share Repurchases | $917.39 Million | -199.84% |
| Other Comprehensive Income | $9.84 Million | +2.14% |
| Other Changes | $89.95 Million | +19.6% |
| Total Change | $- | -44.39% |
Book Value vs Market Value Analysis
This analysis compares Medpace Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 26.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 30.57x to 26.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $13.66 | $417.54 | x |
| 2015-12-31 | $10.43 | $417.54 | x |
| 2016-12-31 | $16.81 | $417.54 | x |
| 2017-12-31 | $12.64 | $417.54 | x |
| 2018-12-31 | $15.98 | $417.54 | x |
| 2019-12-31 | $19.33 | $417.54 | x |
| 2020-12-31 | $21.37 | $417.54 | x |
| 2021-12-31 | $25.28 | $417.54 | x |
| 2022-12-31 | $11.48 | $417.54 | x |
| 2023-12-31 | $17.55 | $417.54 | x |
| 2024-12-31 | $25.79 | $417.54 | x |
| 2025-12-31 | $15.55 | $417.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medpace Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 98.27%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.83%
- • Asset Turnover: 1.28x
- • Equity Multiplier: 4.30x
- Recent ROE (98.27%) is above the historical average (27.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -3.87% | -5.37% | 0.26x | 2.73x | $-55.77 Million |
| 2015 | -2.10% | -2.42% | 0.36x | 2.38x | $-50.02 Million |
| 2016 | 2.20% | 3.18% | 0.43x | 1.60x | $-47.65 Million |
| 2017 | 7.77% | 8.97% | 0.46x | 1.89x | $-11.23 Million |
| 2018 | 12.41% | 10.39% | 0.73x | 1.64x | $14.21 Million |
| 2019 | 13.83% | 11.67% | 0.75x | 1.57x | $27.81 Million |
| 2020 | 18.04% | 15.70% | 0.67x | 1.73x | $64.81 Million |
| 2021 | 19.08% | 15.92% | 0.69x | 1.74x | $86.56 Million |
| 2022 | 63.50% | 16.81% | 1.08x | 3.50x | $206.73 Million |
| 2023 | 50.60% | 15.00% | 1.14x | 2.96x | $226.91 Million |
| 2024 | 48.98% | 19.17% | 1.00x | 2.54x | $321.83 Million |
| 2025 | 98.27% | 17.83% | 1.28x | 4.30x | $405.22 Million |
Industry Comparison
This section compares Medpace Holdings Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $543,908,184
- Average return on equity (ROE) among peers: -221.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medpace Holdings Inc (MEDP) | $459.07 Million | -3.87% | 3.30x | $11.92 Billion |
| Agilent Technologies Inc (A) | $2.51 Billion | -1.24% | 2.04x | $32.42 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $7.19 Million |
| Applied DNA Sciences Inc (APDN) | $11.11 Million | -144.24% | 0.30x | $3.99 Million |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | -204.87% | 0.51x | $9.85 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.21 Billion |
| Burning Rock Biotech Ltd (BNR) | $2.42 Billion | -16.82% | 0.10x | $154.44 Million |
| CareDx Inc (CDNA) | $430.91 Million | -17.78% | 0.26x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medica… Read more